The Indian patents office has awarded a license to Natco Pharma to manufacture and sell a generic version of Bayer's cancer treatment drug Nexavar.

BioLife Solutions has executed an amendment to its current commercial lease to double the area of its existing facilities.

The FDA has granted acceptable status, under its current regulatory guidelines, to Eurogentec's Seraing, Belgium drug substance manufacturing facility.

Dainippon Sumitomo Pharma has obtained manufacturing and marketing approval for Zolpidem tartrate tablets 5mg/10mg [DSP] from the Ministry of Health, Labour and Welfare in Japan.

The European Medicines Agency (EMA) has approved Genzyme’s manufacturing plant in Framingham, Massachusetts, US for the production of Fabrazyme (agalsidase beta).

Progenitor Cell Therapy (PCT), a unit of NeoStem's cell therapy manufacturing, has entered an agreement to provide contract manufacturing and regulatory services related to the development of Islet Sciences' PTM.

German pharmaceutical company Bayer and Yunona Holdings, representing the Ural Pharmaceutical Cluster (UPC) of Russia have entered a memorandum of understanding to manufacture drugs in Russia.

AstraZeneca has invested $200m in a new manufacturing facility in China Medical City, Taizhou, Jiangsu province. The new plant will manufacture both intravenous and oral solid medicines.According to the company, the new plant will help meet the rising demand for its products in China besides extending its availability in urban and rural communities that have limited access to established medicines.

Denmark based CMC Biologics and US based Inspiration Biopharmaceuticals have signed a supply agreement to manufacturing bulk IB1001 as a treatment and preventive measure of bleeding in individuals with hemophilia B.

Sun Pharmaceutical has received the US Food and Drug Administration (FDA) acceptance for its manufacturing plant at Cranbury in New Jersey, US.